PANDORA GENOMICS

PGxReport™ – Clopidogrel
Drug Sensitivity Assay Results

OVERVIEW

Patient:	Jane Smith
Medicine evaluated:	Clopidogrel (Plavix)
Test run:	PGxComplete™
Genes assessed for clinical relevance:	ABCB1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, CYP3A5, PON1
Results:	Ms. Smith was tested for mutations in the genes listed in the table below. These genes are involved in drug metabolism. The genotype of the patient is indicated in column 2.

Gene	Patient genotype	Predicted Outcome	Possible effect on patient
ABCB1	*1 / *1	Normal activity of ABCB1	None
CYP1A2	*1 / *1	Normal activity of CYP1A2	None
CYP2B6	*1 / *1	Normal activity of CYP2B6	None
CYP2C8	*1 / *1	Normal activity of CYP2C8	None
CYP2C9	*1 / *1	Normal activity of CYP2C9	None
CYP2C19	*2 / *2	Decreased activity of CYP2C19	Patients with the *2/*2 genotype are characterized as poor metabolizers.
CYP3A4	*1 / *1	Normal activity of CYP3A4	None
CYP3A5	*1 / *1	Normal activity of CYP3A5	None
PON1	*1 / *1	Normal activity of PON1	None



Legend

- Low confidence
- Medium confidence
- High confidence
- Low risk
- Medium risk
- High risk

Genotype Interpretation Summary

CYP2C19 poor metabolizer status is associated with diminished response to clopidogrel due to a significant decrease in elimination of the drug. Clopidogrel use in poor metabolizers has been associated with adverse clinical outcomes and a worsening of the therapeutic response. It is important to note that genes other than CYP2C19 also mediate clopidogrel metabolism. Other drugs will influence the activity of clopidogrel when taken simultaneously. If Ms. Smith is prescribed any of the medications listed in the table below, consider modifying the clopidogrel treatment plan as indicated by the corresponding arrow.

CONFIDENTIAL Page 1

FIG. 7-1